Urteste

Urteste EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of Urteste (URT.WA) as of Nov 3, 2026 is 2,998.19. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 37.63 — a change of 7,868.59% (higher).

EV/Revenue

2,998.19

YoY

7,868.59%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of Urteste is 2025 2,998.19 . EV/Revenue (Enterprise Value to Revenue) of Urteste was 2024 37.63 . It decreases by 7,868.59% higher compared to the previous year.

The Urteste EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2022
24,997.69 PLN
Jan 1, 2023
40.46 PLN
Jan 1, 2024
37.63 PLN
Jan 1, 2025
2,998.19 PLN
The Urteste EV/Revenue history
YEAREV/RevenueYoY
2,998.19+7,868.59%
37.63-7.00%
40.46-99.84%
24,997.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Urteste Stock analysis

What does Urteste do? Urteste SA develops technology for early cancer detection through urine-based enzyme activity measurement, offering diagnostic tests for multiple cancers including pancreatic, prostate, colorectal, lung, kidney, liver, biliary tract, stomach, esophageal, ovarian, endometrial, breast, leukemia, lymphoma, and glioma. The company operates in the medical devices sector for in vitro diagnostics, targeting healthcare providers and diagnostic laboratories that require early-stage cancer screening solutions. Its products enable non-invasive testing for common cancers, providing a competitive advantage in early detection markets. Urteste SA's business model focuses on selling diagnostic kits and test services directly to hospitals and specialized medical facilities. The firm's technology differentiates itself by analyzing enzyme activity in urine samples, allowing for the detection of various cancers without invasive procedures. This approach appeals to healthcare institutions seeking efficient, cost-effective screening methods for high-risk patient populations. Urteste SA's product portfolio includes specific tests for each listed cancer type, catering to the growing demand for early cancer diagnostics in clinical settings. The company's revenue streams derive from the sale of diagnostic kits and associated testing services to medical facilities that implement these tests in their screening protocols. Urteste SA's target market consists of hospitals, diagnostic laboratories, and specialized medical centers that prioritize early cancer detection as part of their patient care strategies. These institutions purchase the company's diagnostic tests to enhance their screening capabilities and improve patient outcomes through timely interventions. The firm's offerings address the specific needs of healthcare providers looking for reliable, non-invasive methods to detect multiple cancer types simultaneously. By focusing on urinary enzyme analysis, Urteste SA positions itself as a key provider of innovative diagnostic solutions in the cancer screening market. Urteste is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Urteste stock

EV/Revenue (Enterprise Value to Revenue) of Urteste is 2,998.19 in 2025.

EV/Revenue (Enterprise Value to Revenue) of Urteste changed from 37.63 to 2,998.19, representing a 7,868.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) Urteste since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s Urteste with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Urteste

All Key Metrics — Urteste